1235407-01-8

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 3-hydrazinylazetidine-1-carboxylate is utilized as a building block in organic synthesis for the preparation of various organic compounds. Its unique structure and functional groups contribute to the creation of diverse chemical entities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-hydrazinylazetidine-1-carboxylate is employed as a key intermediate for the synthesis of pharmaceuticals. Its presence in the molecular structure of potential drug candidates can influence their pharmacological properties and therapeutic efficacy.
Used in Drug Development:
Tert-butyl 3-hydrazinylazetidine-1-carboxylate is used as a precursor in the development of new drugs. Its potential applications in creating biologically active compounds make it a valuable asset in drug discovery processes, where it can be incorporated into novel therapeutic agents.
Used in Chemical Research:
tert-butyl 3-hydrazinylazetidine-1-carboxylate is also used in chemical research to explore its reactivity, stability, and the possibility of forming new chemical entities. Its role in understanding the fundamental aspects of chemical reactions and the synthesis of complex molecules is significant.

Upstream product

• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 141699-58-3 3-methanesulfonyloxy-azetidine-1-carboxylic acid tert-butyl ester 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 

Downstream Products

• 1354819-31-0 tert-butyl 3-{5-[5-trifluoromethyl-2-(2-chloro-4-{[(2,4-dimethoxybenzyl)(1,3,4-thiadiazol-5-yl)amino]sulfonyl}-5-fluorophenoxy)phenyl]-1H-pyrazol-1-yl}azetidine-1-carboxylate 
• 1235407-23-4 tert-butyl 3-[5-(5-trifluoromethyl-2-hydroxyphenyl)-1H-pyrazol-1-yl]azetidine-1-carboxylate 
• 1354786-87-0 tert-butyl 3-{5-[4-(2-chloro-4-{[(2,4-dimethoxybenzyl)(1,3,4-thiadiazol-2-yl)amino]sulfonyl}-5-fluorophenoxy)-2'-(trifluoromethyl)biphenyl-3-yl]-1H-pyrazol-1-yl}azetidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7

A series of acidic diaryl ether heterocyclic sulfonamides that are potent and subtype selective NaV1.7 inhibitors is described. Optimization of early lead matter focused on removal of structural alerts, improving metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to deliver the desired balance of preclinical in vitro properties. Concerns over nonmetabolic routes of clearance, variable clearance in preclinical species, and subsequent low confidence human pharmacokinetic predictions led to the decision to conduct a human microdose study to determine clinical pharmacokinetics. The design strategies and results from preclinical PK and clinical human microdose PK data are described leading to the discovery of the first subtype selective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage sensing domain.

Chemical Compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z1, Ra, Rb, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

CHEMICAL COMPOUNDS

The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav 1.7 in